Revance Therapeutics (RVNC) Misses Q2 EPS by 2c

Revance Therapeutics (NASDAQ: RVNC) reported Q2 EPS of ($0.88), $0.02 worse than the analyst estimate of ($0.86). Revenue for the quarter came in at $75 thousand versus the consensus estimate of $70 thousand.

For earnings history and earnings-related data on Revance Therapeutics (RVNC) click here.

You May Also Be Interested In

• Paychex (PAYX) Tops Q1 EPS by 2c
• KeyBanc Sees 'A Potential Catalyst for Earnings Growth and Value Creation' for Acadia Realty Trust (AKR)
• TD Cowen on Alaska Air (ALK): 'Can Alaska ReAccelerate?'